Drugs / Tadalafil
Tadalafil
also known as
Cialis · TAD · Adcirca · Adcirca (previously tadalafil lilly) · Chewtadzy · IC-351 · LY-450190 · NSC-750236 · +10 more
Small molecule targets PDE5A
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | CIALIS | — | 2008-01-07 – 2018-02-15 | fda.gov ↗ |
| Approved | US (FDA) | CIALIS | — | 2003-11-21 | fda.gov ↗ |
| Approved | EU (EMA) | Cialis | — | 2002-11-12 | europa.eu ↗ |
Trials 145 · started per year
today
EU approved 2002
US approved 2003
1
2
2
5
3
2
6
10
8
7
5
7
6
9
6
4
1
5
5
8
11
7
9
9
6
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05466695 | Aug 2022 → Jul 2023 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT03238365 | Aug 2017 → Jul 2019 | head and neck carcinoma, laryngeal disorder | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT01359670 | May 2011 → May 2013 | Duchenne muscular dystrophy | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 126 trials | ||||||
| Phase 1 | NCT07117383 | Jan → Mar 2026 overdue | erectile dysfunction | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04762082 | May → Aug 2025 | erectile dysfunction | Seattle Gummy Company | Unknown | No outcome recorded |
| Phase 1 | NCT06553924 | May 2024 | pulmonary arterial hypertension | Humanis | Completed | No outcome recorded |
| Phase 1 | NCT05236231 | Feb → May 2022 | — | Actelion | Completed | No outcome recorded |
| Phase 1 | NCT05095077 | Aug → Dec 2021 | female stress incontinence | University Hospital Bispebjerg and Frederiksberg | Completed | No outcome recorded |
| Phase 1 | NCT04757662 | May 2021 → Jun 2023 | astrocytoma (excluding glioblastoma) | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04540744 | Apr → Aug 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04235270 | Jan → Jul 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02998736 | Nov 2017 → Sep 2022 | digestive system cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT03215966 | Aug → Sep 2017 | — | Actelion | Completed | No outcome recorded |
| Phase 1 | NCT02839122 | May → Sep 2016 | benign prostatic hyperplasia | Yuyu Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02544880 | Apr 2016 → Jun 2019 | head and neck squamous cell carcinoma | Donald T. Weed, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT02688387 | Mar 2016 → Aug 2017 | pulmonary hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02615782 | Dec 2015 → Apr 2016 | benign prostatic hyperplasia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02352311 | Jan → Jun 2015 | benign prostatic hyperplasia | Dongkook Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02300259 | Nov 2014 → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02247505 | Sep → Oct 2014 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02239484 | Mar → Sep 2014 | benign prostatic hyperplasia, erectile dysfunction | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01942551 | Sep → Dec 2013 | benign prostatic hyperplasia | Dongkook Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01903083 | Jul 2013 → Dec 2017 | — | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT01580501 | Mar 2012 → Mar 2013 | Duchenne muscular dystrophy | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01291069 | Sep 2011 → Feb 2014 | univentricular heart | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT01342224 | Jan 2011 → Jun 2012 | pancreatic adenocarcinoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT01244620 | Nov → Dec 2010 | pulmonary arterial hypertension | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01183650 | Jul 2010 → Apr 2011 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02253862 | Dec 2005 → Mar 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07206706 | May → Dec 2022 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1/2 | NCT05030623 | Aug 2021 → Dec 2024 | major depressive disorder | Sadat City University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01484431 | Jul 2012 → Apr 2017 | pulmonary arterial hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT01544998 | Feb 2012 → Aug 2013 | congestive heart failure | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00274430 | Jul → Sep 2003 | high altitude pulmonary edema | University of Zurich | Completed | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT07576335 | May 2026 → Feb 2028 expected | prostate cancer | Surgical Outcomes Research Centre (SOuRCe) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06290713 | Jun 2024 → Nov 2026 expected | Duchenne muscular dystrophy | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT05709574 | Apr 2023 → Jun 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05014776 | Aug 2022 → Apr 2024 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT05173896 | May 2022 → Sep 2024 overdue | ischemic stroke | Christina Kruuse | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05142254 | Apr 2022 → Jul 2023 | priapism | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03993353 | Apr 2020 → Apr 2022 | esophageal cancer, head and neck squamous cell carcinoma, malignant tumor of neck, metastatic malignant neoplasm +1 | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT07333976 | Jan 2020 → Dec 2023 | chemotherapy-induced neuropathy, metastatic prostate carcinoma, toxic polyneuropathy | Tri-Service General Hospital (TSGH) | Completed | No outcome recorded |
| Phase 2 | NCT04069936 | Oct 2019 → Oct 2021 | non-small cell lung carcinoma | WindMIL Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT03785210 | Jun 2019 → Oct 2022 | colorectal cancer, hepatocellular carcinoma, malignant pancreatic neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT02611258 | Jul 2016 → Jan 2021 | intrinsic cardiomyopathy | Andrea M. Isidori | Completed | No outcome recorded |
| Phase 2 | NCT02611336 | Jul 2016 → Jan 2021 | acromegaly | Andrea M. Isidori | Completed | No outcome recorded |
| Phase 2 | NCT02601989 | Nov 2015 → Jan 2019 | type 2 diabetes mellitus | Göteborg University | Completed | No outcome recorded |
| Phase 2 | NCT02194465 | Aug 2014 → Mar 2015 | essential hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01862536 | Oct 2013 → Aug 2019 | chronic obstructive pulmonary disease, pulmonary hypertension owing to lung disease and/or hypoxia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01374217 | Apr 2012 → Jan 2014 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT01160289 | Oct 2010 → Nov 2011 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00783094 | Nov 2008 → Jun 2009 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00540124 | Oct 2007 → Jun 2008 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00894413 | May 2007 → Mar 2012 | head and neck squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00538564 | Nov 2006 → Aug 2009 | priapism, sickle cell disease | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00157326 | Sep 2005 → Jun 2006 | hypertensive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00174486 | Feb → Jun 2005 | erectile dysfunction | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00707187 | Jul 2001 → Jul 2002 | systemic sclerosis | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00334477 | — | erectile dysfunction | University of Pernambuco | Unknown | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06583590 | Aug 2024 → Aug 2025 overdue | erectile dysfunction | Aswan University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05971667 | Jul → Oct 2023 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05955001 | Apr 2023 → Jul 2025 overdue | erectile dysfunction | Mansoura University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05195775 | Dec 2021 → Sep 2025 overdue | Duchenne muscular dystrophy | University of Florida | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01324999 | Mar 2011 → Jul 2013 | pulmonary hypertension | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 333 trials | ||||||
| Phase 3 | NCT06805513 | Jan 2025 → Mar 2026 | erectile dysfunction | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT06520839 | May → Dec 2024 overdue | erectile dysfunction | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| Phase 3 | NCT06466369 | Mar → Jul 2024 | benign prostatic hyperplasia | Al-Azhar University | Completed | No outcome recorded |
| Phase 3 | NCT05844462 | Feb 2024 → Sep 2027 expected | chronic obstructive pulmonary disease, pulmonary hypertension | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT06707181 | Nov 2023 → May 2024 | ureterolithiasis | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT05206955 | Sep 2022 → Nov 2026 expected | univentricular cardiopathy | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 3 | NCT05179876 | May 2022 → Jan 2027 expected | pulmonary hypertension | Actelion | Recruiting | No outcome recorded |
| Phase 3 | NCT05487755 | Feb 2022 → Mar 2023 | diabetic kidney disease | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT04984993 | Sep 2021 → Jul 2022 | erectile dysfunction | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04361305 | Jun 2020 → Jan 2021 | erectile dysfunction, premature ejaculation | Yan-Ping Huang | Unknown | No outcome recorded |
| Phase 3 | NCT03904693 | Jul 2019 → Aug 2022 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT04052269 | Jun 2019 → Oct 2021 | glaucoma | Imperial College London | Suspended | No outcome recorded |
| Phase 3 | NCT03905018 | May → Sep 2019 | — | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 3 | NCT03246880 | Sep 2015 → Apr 2016 | benign prostatic hyperplasia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01824290 | Feb 2014 → Mar 2019 | pulmonary arterial hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01960153 | Oct 2013 → Dec 2017 | heart failure, pulmonary hypertension | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT01865084 | Sep 2013 → Dec 2015 | Duchenne muscular dystrophy | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01937871 | Sep 2013 → Dec 2015 | benign prostatic hyperplasia, erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01460342 | Dec 2011 → Oct 2012 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01139762 | Sep 2010 → Feb 2012 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01152190 | Sep 2010 → Jul 2012 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00931528 | Nov 2009 → Dec 2012 | prostate cancer, sexual disorder | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01117298 | Nov 2009 → Apr 2010 | Raynaud disease, scleroderma | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00970632 | Oct 2009 → Jan 2011 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00861757 | Mar 2009 → Jun 2010 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00855582 | Mar 2009 → Jul 2010 | benign prostatic hyperplasia, erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00848081 | Mar → Dec 2009 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00827242 | Jan → Nov 2009 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00836693 | Jan 2009 → Jan 2010 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00734604 | Aug 2008 → Sep 2009 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00215631 | Oct → Nov 2005 | erectile dysfunction, prostate cancer | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00421083 | Sep 2004 → Jun 2005 | erectile dysfunction, spinal cord injury | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00122499 | Feb 2003 → Feb 2005 | erectile dysfunction, prostate cancer | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 431 trials | ||||||
| Phase 4 | NCT07642505 | Jun → Nov 2026 expected | erectile dysfunction | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT07654413 | Jun 2026 → Nov 2027 expected | benign prostatic hyperplasia, urinary tract obstruction | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT07391579 | Dec 2025 → Dec 2026 expected | erectile dysfunction | Mansoura University | Recruiting | No outcome recorded |
| Phase 4 | NCT07416968 | Sep 2025 → Sep 2026 expected | overactive bladder | Mansoura University | Recruiting | No outcome recorded |
| Phase 4 | NCT07602608 | Apr → Dec 2025 | erectile dysfunction | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT07574268 | Jun 2024 → Oct 2025 | erectile dysfunction | Menoufia University | Completed | No outcome recorded |
| Phase 4 | NCT06947265 | Jan 2024 → Jan 2025 | erectile dysfunction | Fayoum University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07499804 | Oct 2023 → Apr 2026 overdue | female infertility | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT06809205 | Apr 2023 → May 2024 | benign prostatic hyperplasia | Fayoum University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03177746 | Dec 2022 → Jan 2023 | erectile dysfunction, premature ejaculation | Neutec Ar-Ge San ve Tic A.Ş | Unknown | No outcome recorded |
| Phase 4 | NCT05051436 | Dec 2021 → Aug 2026 overdue | obesity disorder, prediabetes syndrome | Philip Kern | Recruiting | No outcome recorded |
| Phase 4 | NCT04946162 | Apr 2020 | COVID-19, acute respiratory distress syndrome | Santa Barbara Cottage Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT03309592 | Oct 2017 → Nov 2018 | cirrhosis of liver, pulmonary hypertension | Ochsner Health System | Withdrawn | No outcome recorded |
| Phase 4 | NCT02943356 | Jul 2016 → Jul 2017 | erectile dysfunction, hypogonadism, male | The Catholic University of Korea | Unknown | No outcome recorded |
| Phase 4 | NCT02252367 | Dec 2015 → Jan 2019 | benign prostatic hyperplasia | University of Florence | Completed | No outcome recorded |
| Phase 4 | NCT02968901 | Sep 2015 → Sep 2018 | pulmonary arterial hypertension | Actelion | Terminated | No outcome recorded |
| Phase 4 | NCT02595684 | Aug → Nov 2015 | obesity disorder | University of Guadalajara | Completed | No outcome recorded |
| Phase 4 | NCT02431754 | Apr 2015 → Feb 2016 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT02224846 | Oct 2014 → May 2016 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03236818 | May 2013 → Sep 2017 | pulmonary arterial hypertension | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 4 | NCT01352507 | Jun 2011 → Jun 2012 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01326117 | Apr 2011 → Dec 2013 | gastroparesis | Mark Feinglos | Withdrawn | No outcome recorded |
| Phase 4 | NCT01122264 | May 2010 → Jun 2011 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01070511 | Jan 2010 → Dec 2012 | Becker muscular dystrophy | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01042158 | Jan 2010 → Nov 2014 | pulmonary arterial hypertension, systemic sclerosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01026818 | Nov 2009 → Oct 2012 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00833638 | Feb → Jun 2009 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00705588 | Aug 2008 → Jan 2010 | pulmonary arterial hypertension | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00333281 | Jun 2005 → Aug 2006 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00422578 | Oct 2004 → Sep 2005 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT07715448 | ? → Jan 2026 | benign prostatic hyperplasia, erectile dysfunction | Beni-Suef University | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT07707505 | Aug 2026 → Jan 2027 expected | — | Medipol University | Not yet recruiting | No outcome recorded |
| — | NCT07690566 | Sep → Dec 2025 | — | Deraya University | Completed | No outcome recorded |
| — | NCT07312955 | May → Nov 2025 | overactive bladder | Ain Shams University | Completed | No outcome recorded |
| — | NCT06968962 | May 2025 → May 2028 expected | pulmonary arterial hypertension | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT06962462 | May → Aug 2025 overdue | diabetes mellitus type 2 associated cataract | South Valley University | Not yet recruiting | No outcome recorded |
| — | NCT06543628 | Aug 2024 → Mar 2025 | erectile dysfunction | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT05823506 | Feb → Dec 2023 | erectile dysfunction | Saint Petersburg State University, Russia | Unknown | No outcome recorded |
| — | NCT05789732 | Mar → Aug 2022 | ureterolithiasis | Benha University | Completed | No outcome recorded |
| — | NCT05109377 | Jun → Nov 2021 | erectile dysfunction | Ankara Training and Research Hospital | Unknown | No outcome recorded |
| — | NCT03566914 | Jun 2018 → Dec 2019 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT02304679 | Jul 2015 → Feb 2018 | erectile dysfunction | Nîmes University Hospital | Completed | No outcome recorded |
| — | NCT01564303 | May → Nov 2012 | — | The Nazareth Hospital | Unknown | No outcome recorded |
| — | NCT00843635 | Sep 2008 → Apr 2015 | head and neck cancer | Donald T. Weed | Completed | No outcome recorded |
| — | NCT00822354 | Sep 2008 → Feb 2010 | Raynaud disease | Northwestern University | Completed | No outcome recorded |
| — | NCT00506701 | Feb 2008 → Feb 2010 | chronic obstructive pulmonary disease | Herlev Hospital | Withdrawn | No outcome recorded |
| — | NCT00463957 | Aug 2006 → ? | erectile dysfunction | University of Cambridge | Unknown | No outcome recorded |
| — | NCT01060969 | Jan 2006 → Aug 2010 | brain edema, pulmonary edema | Sheba Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 98 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07447518 Comparator | Sep 2022 → Jan 2023 | — | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 0 | NCT02653833 Background | Nov 2017 → Sep 2018 | muscular dystrophy | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT07466030 Comparator | Mar 2026 → Mar 2028 expected | benign prostatic hyperplasia | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04500860 Comparator | Dec 2020 → Jul 2022 | overactive bladder | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03166787 Background | Aug 2017 → Apr 2020 | — | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT03240939 Comparator | Mar → Jul 2017 | benign prostatic hyperplasia | Yuyu Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02645890 Comparator | Nov → Dec 2015 | benign prostatic hyperplasia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01401543 Comparator | Jul → Sep 2011 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01238224 Comparator | Nov 2009 → Nov 2011 | type 2 diabetes mellitus | Vastra Gotaland Region | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02058095 Comparator | Mar 2014 → Jun 2019 | cardiomyopathy, impaired renal function disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01970176 Comparator | Jan 2014 → Sep 2019 | cardiomyopathy, impaired renal function disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07537855 Background | Jun 2026 → Jun 2028 expected | erectile dysfunction | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07231185 Comparator | Jan → Mar 2026 overdue | erectile dysfunction | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07172815 Comparator | Sep 2025 → Aug 2028 expected | Alzheimer disease | Imperial College London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05937854 Comparator | Apr 2024 → Mar 2029 expected | chronic obstructive pulmonary disease, pulmonary hypertension | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT05558007 Comparator | Nov 2023 → Dec 2024 overdue | erectile dysfunction, prostate cancer | Biozeus Biopharmaceutical S.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT04684589 Comparator | Mar 2021 → Jun 2025 | obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04483115 Comparator | Nov 2020 → Jun 2022 | pulmonary arterial hypertension | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02801032 Comparator | Nov 2016 → Aug 2017 | stroke disorder | Christina Kruuse | Completed | No outcome recorded |
| Phase 2 | NCT02819440 Comparator | Jul 2016 → Jun 2020 | obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02450253 Comparator | Sep 2015 → Jan 2018 | vascular dementia | St George's, University of London | Completed | No outcome recorded |
| Phase 2 | NCT01697800 Comparator | Sep 2012 → Jul 2014 | head and neck squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT01423370 Comparator | Nov 2011 → Mar 2013 | erectile dysfunction | Yuhan Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01197469 Comparator | Sep 2010 → Sep 2012 | chronic obstructive pulmonary disease, pulmonary hypertension owing to lung disease and/or hypoxia | University of Dundee | Completed | No outcome recorded |
| Phase 2 | NCT01200732 Comparator | Feb 2008 → Jul 2010 | Eisenmenger syndrome | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00386009 Comparator | Oct 2006 → May 2008 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00547625 Comparator | Oct 2004 → Jul 2005 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00050609 Comparator | Feb → Sep 2003 | gastroparesis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05266651 Comparator | Mar → May 2022 | sexual disorder | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00384930 Comparator | Aug 2006 → Oct 2007 | benign prostatic hyperplasia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 327 trials | ||||||
| Phase 3 | NCT07245680 Background | Apr 2026 → Feb 2029 expected | pulmonary arterial hypertension | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT07177326 Comparator | Oct 2025 → Oct 2026 expected | erectile dysfunction | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06717711 Background | Aug 2024 → Aug 2025 overdue | erectile dysfunction, malignant urinary system neoplasm, prostate carcinoma | Regina Elena Cancer Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT05052879 Comparator | Jul 2024 → May 2026 overdue | erectile dysfunction, premature ejaculation | EMS | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04947631 Comparator | Jul 2021 → Jun 2023 | benign prostatic hyperplasia | Dongkook Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04433559 Comparator | Aug 2020 → Aug 2021 | psychosexual disorder | Lidia Larrañaga | Unknown | No outcome recorded |
| Phase 3 | NCT04703127 Comparator | Mar 2020 → Jan 2021 | premature ejaculation | Sohag University | Unknown | No outcome recorded |
| Phase 3 | NCT03049540 Comparator | Oct 2017 → Oct 2021 | congenital heart disease, congenitally corrected transposition of the great arteries | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 3 | NCT02558231 Background | May 2016 → Aug 2019 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT02862483 Background | Mar 2016 → Mar 2017 | benign prostatic hyperplasia, erectile dysfunction | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT01910389 Comparator | Nov 2013 → Feb 2014 | heart failure, pulmonary hypertension | Carelon Research | Terminated | No outcome recorded |
| Phase 3 | NCT01553981 Comparator | Mar 2012 → Apr 2014 | interstitial lung disease | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01444651 Comparator | Aug 2011 → Mar 2013 | cardiovascular disorder, glucose intolerance, obesity disorder | Thomas J. Wang, MD | Completed | No outcome recorded |
| Phase 3 | NCT01178073 Comparator | Oct 2010 → Jul 2014 | pulmonary arterial hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01063855 Background | Apr 2010 → Aug 2011 | erectile dysfunction, sexual disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00626665 Comparator | Dec 2007 → Apr 2008 | Raynaud disease | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00422734 Comparator | Nov 2006 → Jan 2008 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00549302 Comparator | Dec 2005 → Feb 2012 | pulmonary arterial hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00125918 Comparator | Aug 2005 → Aug 2007 | pulmonary hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00547183 Comparator | Oct 2004 → May 2005 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00547495 Comparator | Mar → Nov 2004 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00668109 Comparator | Dec 2003 → Jun 2004 | erectile dysfunction | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00381732 Comparator | Oct 2003 → Jun 2006 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00547417 Comparator | Jul 2003 → Mar 2004 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00547573 Comparator | Apr → Dec 2003 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00547287 Comparator | Nov 2002 → May 2004 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00547508 Comparator | Oct 2002 → Sep 2003 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 427 trials | ||||||
| Phase 4 | NCT07636161 Background | Sep 2026 → Sep 2027 expected | type 2 diabetes mellitus | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07563647 Comparator | May 2025 → Mar 2026 | diastolic heart failure, erectile dysfunction, metabolic syndrome X | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT06317805 Background | Dec 2023 → Jun 2027 expected | pulmonary arterial hypertension | AOP Orphan Pharmaceuticals AG | Recruiting | No outcome recorded |
| Phase 4 | NCT05537272 Comparator | Sep 2022 → Sep 2023 | urinary bladder disorder | University Hospital of Split | Unknown | No outcome recorded |
| Phase 4 | NCT05494567 Comparator | Nov 2021 → Aug 2022 | benign prostatic hyperplasia, overactive bladder | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT05818670 Comparator | Nov 2020 → Sep 2021 | benign prostatic hyperplasia | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT04641507 Comparator | Jan 2020 → Mar 2022 | ureterolithiasis | Beni-Suef University | Unknown | No outcome recorded |
| Phase 4 | NCT05446493 Comparator | Apr 2019 → Mar 2021 | erectile dysfunction | Aswan University | Completed | No outcome recorded |
| Phase 4 | NCT03229889 Comparator | Jun 2017 → Mar 2022 | nephrolithiasis | University of California, Irvine | Completed | No outcome recorded |
| Phase 4 | NCT02891850 Comparator | Jan 2017 → Jan 2020 | pulmonary arterial hypertension | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT02554045 Comparator | Jan → Jun 2015 | obesity disorder, sexual disorder | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 4 | NCT02225548 Background | Sep 2014 → Dec 2018 | Parkinson disease, erectile dysfunction | University of South Florida | Unknown | No outcome recorded |
| Phase 4 | NCT01803828 Comparator | May 2014 → Jan 2019 | intrinsic cardiomyopathy, type 2 diabetes mellitus | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 4 | NCT01275339 Comparator | Dec 2012 → Apr 2017 | aortic valve stenosis | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT01364701 Comparator | Jun 2011 → Jun 2012 | erectile dysfunction | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 4 | NCT01302444 Comparator | Mar 2011 → Mar 2012 | pulmonary arterial hypertension | Rhode Island Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01272388 Comparator | Jan → Apr 2011 | aortic valve stenosis | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT01130532 Comparator | Aug 2010 → Jan 2012 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01305252 Comparator | Jul 2010 → Sep 2014 | pulmonary arterial hypertension | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01067391 Comparator | Oct 2009 → Jul 2015 | hypotensive disorder, spinal cord injury | University of Manitoba | Completed | No outcome recorded |
| Phase 4 | NCT00617305 Background | Apr 2008 → Feb 2011 | pulmonary arterial hypertension | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00547352 Comparator | Jun 2004 → Jun 2005 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00663130 Comparator | Apr → Jul 2004 | erectile dysfunction | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00382135 Comparator | Nov 2003 → Dec 2005 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00547092 Comparator | Oct 2003 → Nov 2004 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00644956 Comparator | Jun → Nov 2003 | erectile dysfunction | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00547599 Comparator | Apr 2003 → Jan 2004 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT07562282 Comparator | Dec 2025 → Jul 2026 overdue | ureterolithiasis, urolithiasis | Ain Shams University | Recruiting | No outcome recorded |
| — | NCT06213077 Comparator | Dec 2023 → Apr 2024 | erectile dysfunction | RHA Investments Ltd | Unknown | No outcome recorded |
| — | NCT06350773 Comparator | Jun 2023 → Dec 2025 overdue | pulmonary hypertension | Beni-Suef University | Active not recruiting | No outcome recorded |
| — | NCT05787769 Comparator | Mar 2023 → Jan 2025 | — | Mansoura University | Unknown | No outcome recorded |
| — | NCT06184334 Comparator | Sep → Dec 2022 | overactive bladder | Elsayed Abdelhalim Elsayed | Completed | No outcome recorded |
| — | NCT05236634 Comparator | May 2022 → May 2024 | benign prostatic hyperplasia | Assiut University | Unknown | No outcome recorded |
| — | NCT05146674 Comparator | Jan → Dec 2022 | — | Mansoura University | Unknown | No outcome recorded |
| — | NCT05199727 Comparator | Sep 2021 → Mar 2022 | erectile dysfunction | Menoufia University | Unknown | No outcome recorded |
| — | NCT04623840 Comparator | Oct 2020 → Feb 2021 | erectile dysfunction | Cairo University | Unknown | No outcome recorded |
| — | NCT03834610 Comparator | Oct 2017 → Oct 2018 | erectile dysfunction | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT04446598 Comparator | Mar 2017 → Nov 2018 | chronic prostatitis | Adrian Gaspar | Completed | No outcome recorded |
| — | NCT01661595 Comparator | Nov 2012 → Jun 2015 | — | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| — | NCT01743911 Comparator | Sep 2010 → Apr 2012 | hypertensive disorder | University of Campinas, Brazil | Completed | No outcome recorded |
| — | NCT00750308 Comparator | Dec 2006 → Jan 2009 | metabolic syndrome X | Vanderbilt University | Completed | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-21 | Sanofi | Press Release: Opella reaches study milestone for Cialis sanofi.com ↗ |
| 2022-05-30 | Sanofi | Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial sanofi.com ↗ |
| 2019-02-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of ALYQ™ (Tadalafil Tablets USP), a Generic Version of ADCIRCA® in the United States tevapharm.com ↗ |
| 2015-10-02 | Gilead Sciences | U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1) gilead.com ↗ |
| 2015-08-26 | Gilead Sciences | Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine gilead.com ↗ |
| 2014-09-08 | Gilead Sciences | First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study gilead.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 248 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tadalafil | “Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED)...” NCT01063855 ↗239“All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one...” NCT06317805 ↗ “Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the...” NCT01564303 ↗ “Oral administration of a daily low-dose PDE5 inhibitor (e.g., Tadalafil 5 mg once daily) for a continuous duration of 6 months, aligning with standard clinical guidelines for...” NCT07707505 ↗ “Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection.” NCT05787769 ↗ “This study evaluates the effect of 5 mg daily tadalafil therapy on serum levels of Endothelin-1 and E-selectin in diabetic male patients with erectile dysfunction.” NCT06962462 ↗ “Evaluation of safety and efficacy of Tamsulosin 0.4 mg plus Tadalafil 2.5 mg versus Tamsulosin 0.4 mg plus Tadalafil 5 mg in relieving stent-related symptoms.” NCT07562282 ↗ “Ro Sparks® is a combination sildenafil + tadalafil product administered on an on-demand basis.” NCT07231185 ↗ “study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.” NCT04052269 ↗ “Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks.” NCT05236634 ↗ “Group C was treated with a combination of silodosin 8 mg and tadalafil 5 mg .” NCT06707181 ↗ “Arm A:Tamsulosin/ Tadalafil Fixed dose combination” NCT02645890 ↗ “get 5 mg oral tadalafil for 8 weeks” NCT06947265 ↗ “5 mg Tadalafil per day for 1 month” NCT02304679 ↗ “Tamsulosin HCl/Tadalafil 0.2/5mg” NCT02615782 ↗ “Tadalafil 5 mg” NCT02352311 ↗ “Tadalafil 5mg” NCT02247505 ↗ |
| Known as | Adcirca | “Tadalafil (Adcirca®)” NCT03215966 ↗ |
| Known as | Adcirca (previously tadalafil lilly) | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Chewtadzy | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Cialis | “A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra...” NCT00644956 ↗8“Can Tadalafil (Cialis)® Maintain Erectile Function In Patients Treated With External-beam Radiotherapy For Prostate Cancer?” NCT00215631 ↗ “Tadalafil (Cialis®; Eli Lilly) is widely prescribed for erectile dysfunction in men.” NCT02801032 ↗ “CIALIS (tadalafil) tablet 5 mg” NCT02352311 ↗ “Cialis (Tadalafil)” NCT00174486 ↗ |
| Known as | IC-351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | LY-450190 | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | NSC-750236 | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | NSC-759172 | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | TAD | “INTRODUCTION: Tadalafil (TAD) 5 mg coadministered with finasteride (FIN) 5 mg significantly improves lower urinary tract symptoms (LUTS) in men with benign prostatic...” PMID 25353053 ↗ Oct 20142“AIMS: To investigate the efficacy and safety of tadalafil (TAD) versus pentoxifylline (PTX) in the management of diabetic kidney disease (DKD).” PMID 38915115 ↗ Jun 2024 “tadalafil (TAD) is approved for both PRN and once-a-day (OaD) dosing for ED.” PMID 25455432 ↗ Dec 2014 |
| Known as | Tadalafil Citrate | “Drug: Tadalafil Citrate” NCT01291069 ↗ |
| Known as | Tadalafil component of entadfi | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Tadalafil component of opsynvi | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Tadalafil lilly | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Tadalafil mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Tadalafilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Tadliq | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Talmanco (previously tadalafil generics) | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Known as | Trans-tadalafil | ChEMBL registry synonym — accepted as the source's own label CHEMBL779 ↗ |
| Action | Inhibit | “Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway.” PMID 19470885 ↗ May 2009 |
| Modality | Small molecule | “a compound selectively inhibiting the breakdown of cGMP, the PDE5 inhibitor tadalafil.” NCT02801032 ↗ |
| Route | Oral | “taken by mouth” NCT00050609 ↗ |
| Target | PDE5A | “tadalafil target: PDE5A: rs12646525, rs3806808” NCT06520839 ↗ |